Table 1.
Characteristics of the enrolled patients.
| Characteristics | Patients with Left Breast Cancer (n = 55) | Patients with Right Breast Cancer (n = 48) | p-Value | |
|---|---|---|---|---|
| Age (years) | 51.2 ± 9.9 * | 51.4 ± 9.7 * | 0.928 | |
| Menopausal status | Premenopausal | 22 (40.0%) | 17 (35.4%) | 0.634 |
| Postmenopausal | 33 (60.0%) | 31 (64.6%) | ||
| Histopathology | Intraductal carcinoma | 48 (87.3%) | 41 (85.4%) | 0.785 |
| Intralobular carcinoma | 7 (12.7%) | 7 (14.6%) | ||
| T stage | T1 | 33 (60.0%) | 35 (72.9%) | 0.191 |
| T2 | 19 (34.5%) | 9 (18.8%) | ||
| T3 | 3 (5.5%) | 4 (8.3%) | ||
| Lymph node metastasis | Absence | 41 (74.5%) | 34 (70.8%) | 0.674 |
| Presence | 14 (25.5%) | 14 (29.2%) | ||
| Tumor size (cm) | 1.82 ± 1.20 * | 2.09 ± 1.13 * | 0.252 | |
| Histologic grade | Grade 1 | 17 (30.9%) | 15 (31.2%) | 0.980 |
| Grade 2 | 28 (50.9%) | 25 (52.1%) | ||
| Grade 3 | 10 (18.2%) | 8 (16.7%) | ||
| Estrogen receptor status | Positive | 49 (89.1%) | 39 (81.2%) | 0.263 |
| Negative | 6 (10.9%) | 9 (18.8%) | ||
| Progesterone receptor status | Positive | 42 (76.4%) | 30 (62.5%) | 0.128 |
| Negative | 13 (23.6%) | 18 (37.5%) | ||
| HER2 status | Positive | 27 (49.1%) | 23 (47.9%) | 0.906 |
| Negative | 28 (50.9%) | 25 (52.1%) | ||
| Triple negative tumor | 2 (3.6%) | 3 (6.2%) | 0.662 | |
| Ki67 expression status | Positive (≥14%) | 29 (52.7%) | 27 (56.2%) | 0.722 |
| Negative (<14%) | 26 (47.3%) | 21 (43.7%) | ||
| Hypertension | Yes | 8 (14.5%) | 11 (22.9%) | 0.277 |
| No | 47 (85.5%) | 37 (77.1%) | ||
| Diabetes mellitus | Yes | 8 (14.5%) | 9 (18.8%) | 0.568 |
| No | 47 (85.5%) | 39 (81.2%) | ||
| Dyslipidemia medication | Yes | 2 (3.6%) | 3 (6.3%) | 0.540 |
| No | 53 (96.4%) | 45 (93.7%) | ||
| Serum total cholesterol level on staging blood tests | 187 ± 29 * | 194 ± 35 * | 0.340 | |
| Serum triglyceride level on staging blood tests | 143 ± 95 * | 134 ± 103 * | 0.662 | |
| Adjuvant treatment | CTx+RT+Hx | 37 (67.3%) | 26 (54.2%) | 0.322 |
| RT+Hx | 17 (30.9%) | 18 (37.5%) | ||
| CTx+RT | 1 (1.8%) | 3 (6.2%) | ||
| RT alone | 0 (0.0%) | 1 (2.1%) | ||
| Chemotherapy regimen | AC | 14 (25.5%) | 9 (18.8%) | 0.551 |
| TAC | 11 (20.0%) | 12 (25.0%) | ||
| CMF | 8 (14.5%) | 7 (14.6%) | ||
| FAC | 3 (5.5%) | 1 (2.1%) | ||
| FEC | 2 (3.6%) | 0 (0.0%) | ||
| Prescribed total radiation dose (Gy) | Whole breast RT dose | Median, 50.4 (range, 50–50.4) |
Median, 50.4 (range, 45–50.4) |
0.440 |
| Boost RT dose | Median, 16 (range, 8–16) |
Median, 16 (range, 10–16) |
0.225 | |
| Boost RT location | UOQ | 24 (49%) | 24 (57.1%) | 0.077 |
| UIQ | 11 (22.4%) | 10 (23.8%) | ||
| LOQ | 4 (8.2%) | 6 (14.3%) | ||
| LIQ | 4 (8.2%) | 2 (4.8%) | ||
| Central | 6 (12.2%) | 0 (0%) | ||
| Interval between CTx and PET2 (days) | 11.9 ± 4.6 * | 13.5 ± 6.3 * | 0.322 | |
| Interval between RT and PET3 (days) | 139.7 ± 28.1 * | 132.0 ± 28.2 * | 0.170 | |
| Interval between RT and PET4 (days) | 357.4 ± 50.2 * | 363.6 ± 49.3 * | 0.605 | |
* Expressed as average ± standard deviation. HER2, human epidermal growth factor receptor 2; CTx, chemotherapy; RT, radiotherapy; Hx, hormonal therapy; AC, doxorubicin and cyclophosphamide; TAC, docetaxel, doxorubicin, and cyclophosphamide; CMF, cyclophosphamide, methotrexate, and fluorouracil; FAC, fluorouracil, doxorubicin, and cyclophosphamide; FEC, fluorouracil, epirubicin, and cyclophosphamide; UOQ, upper outer quadrant; UIQ, upper inner quadrant; LOQ, lower outer quadrant; LIQ, lower inner quadrant; PET2, post-chemotherapy positron emission tomography/computed tomography (PET/CT); PET3, post-radiotherapy PET/CT; PET4, surveillance PET/CT after adjuvant treatment.